Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

P0627

Sigma-Aldrich

PTH-glycine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H8N2OS
CAS Number:
2010-15-3
Molecular Weight:
192.24
EC Number:
217-927-3
MDL number:
MFCD00027413
UNSPSC Code:
12352200
PubChem Substance ID:
24898117

storage temp.

−20°C

SMILES string

O=C1CNC(=S)N1c2ccccc2

InChI

1S/C9H8N2OS/c12-8-6-10-9(13)11(8)7-4-2-1-3-5-7/h1-5H,6H2,(H,10,13)

InChI key

ZZRIQDWDJVLELF-UHFFFAOYSA-N

Gene Information

human ... CNR1(1268) , CNR2(1269)
rat ... Faah(29347)

Looking for similar products? Visit Product Comparison Guide

pictograms

Skull and crossbones
GHS06

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
054F5043
019F5032

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sumanta K Pal et al.
Expert opinion on pharmacotherapy, 14(5), 679-685 (2013-02-28)
The FDA approval of docetaxel for metastatic castration-resistant prostate cancer (mCRPC) in 2005 marked a major milestone, as it was the first approved agent for this disease that demonstrated a survival advantage in Phase III assessment of this disease. Since
Manoj P Menon et al.
Current oncology reports, 15(2), 69-75 (2013-01-24)
Enzalutamide, formerly known as MDV3100, is an oral second generation androgen receptor (AR) inhibitor that was chosen from a screen of agents and shown in preclinical studies to have greater affinity for the AR than its predecessors without any agonistic
Y S Ha et al.
Drugs of today (Barcelona, Spain : 1998), 49(1), 7-13 (2013-01-31)
Castration-resistant prostate cancer (CRPC) remains a major clinical challenge, given the mechanistic heterogeneity due to a complex signal transduction network. Enzalutamide (MDV-3100), recently approved by the U.S. Food and Drug Administration (FDA) at a dose of 160 mg/day for the
Enzalutamide (Xtandi) for prostate cancer.
The Medical letter on drugs and therapeutics, 55(1411), e20-e20 (2013-03-08)
New prostate cancer drugs hold promise.
Cancer, 119(2), 247-248 (2013-01-08)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service